Literature DB >> 25929419

Infections caused by Fusobacterium in children: a 14-year single-center experience.

Oded Shamriz1, Dan Engelhard1,2, Violeta Temper3, Shoshana Revel-Vilk4, Shmuel Benenson3, Rebecca Brooks1, Ariel Tenenbaum1, Polina Stepensky4, Benjamin Koplewitz5, Michal Kaufmann6, Diana Averbuch7,8.   

Abstract

PURPOSE: This study aimed at reviewing our experience with infections caused by Fusobacterium in children.
METHODS: A retrospective analysis of medical records of children admitted to Hadassah-Hebrew University Medical Center from 2000 to 2013, in whom Fusobacterium spp. was identified in any specimen.
RESULTS: A total of 22 patients (males = 12) at a mean ± SE age of 5 ± 1 (range 1-17) years, were identified. The most common complication was abscess formation (n = 11, 50 %). Eight children (36.4 %) had intracranial complications, including brain abscess (n = 4), meningitis (n = 4) and cerebral sinus vein thrombosis (CSVT, n = 5). Seventeen children (77 %) had bacteremia. Primary site of infection was otogenic (n = 9), oropharyngeal (n = 7), respiratory (n = 2), sinuses (n = 2), intra-abdominal (n = 1) and mucositis (n = 1). Fourteen cases were caused by Fusobacterium necrophorum, including four cases with CSVT, 7/8 cases of mastoiditis, four of them with subperiosteal abscess formation; all four cases with meningitis and two brain abscesses. Fifteen (68 %) patients required surgical intervention and 3 (14 %) received anti-coagulation therapy. Excluding one patient with overwhelming sepsis with fatal outcome, all patients recovered.
CONCLUSIONS: Fusobacterium infections in children can cause a diverse spectrum of disease and is associated with high rates of abscess formation and intracranial complications. Although Fusobacterium nucleatum is abundant in the oral cavity, F. necrophorum is the main pathogen that causes severe infections in healthy children.

Entities:  

Keywords:  Bacteremia; Clinical spectrum; Complications; Fusobacterium; Lemierre; Otogenic infections

Mesh:

Year:  2015        PMID: 25929419     DOI: 10.1007/s15010-015-0782-x

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  36 in total

1.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Fusobacterial infections: clinical spectrum and incidence of invasive disease.

Authors:  Paul J Huggan; David R Murdoch
Journal:  J Infect       Date:  2008-09-20       Impact factor: 6.072

3.  Primary meningitis caused by Bacteroides fragilis and Fusobacterium necrophorum.

Authors:  A K Islam; J M Shneerson
Journal:  Postgrad Med J       Date:  1980-05       Impact factor: 2.401

Review 4.  Human necrobacillosis, with emphasis on Lemierre's syndrome.

Authors:  L Hagelskjaer Kristensen; J Prag
Journal:  Clin Infect Dis       Date:  2000-09-14       Impact factor: 9.079

Review 5.  Increased diagnosis of Lemierre syndrome and other Fusobacterium necrophorum infections at a Children's Hospital.

Authors:  Susan Ramirez; Tannaz G Hild; Colin N Rudolph; John R Sty; Susan C Kehl; Peter Havens; Kelly Henrickson; Michael J Chusid
Journal:  Pediatrics       Date:  2003-11       Impact factor: 7.124

6.  Fusobacterium invasive infections in children: a retrospective study in two French tertiary care centres.

Authors:  M Bailhache; P Mariani-Kurkdjian; P Lehours; J Sarlangue; P Pillet; E Bingen; A Faye
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-03-08       Impact factor: 3.267

7.  Bacteremia due to Fusobacterium species.

Authors:  S Henry; A DeMaria; W R McCabe
Journal:  Am J Med       Date:  1983-08       Impact factor: 4.965

8.  Fusobacterium necrophorum: most prevalent pathogen in peritonsillar abscess in Denmark.

Authors:  Tejs Ehlers Klug; Maria Rusan; Kurt Fuursted; Therese Ovesen
Journal:  Clin Infect Dis       Date:  2009-11-15       Impact factor: 9.079

9.  Fusobacterium necrophorum mastoiditis in children - emerging pathogen in an old disease.

Authors:  Havatzelet Yarden-Bilavsky; Eyal Raveh; Gilat Livni; Oded Scheuerman; Jacob Amir; Efraim Bilavsky
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2012-10-25       Impact factor: 1.675

10.  Epidemiology and clinical outcomes of patients with Fusobacterium bacteraemia.

Authors:  E A Goldberg; T Venkat-Ramani; M Hewit; H F Bonilla
Journal:  Epidemiol Infect       Date:  2012-04-17       Impact factor: 4.434

View more
  6 in total

1. 

Authors:  Karen Arane; Ran D Goldman
Journal:  Can Fam Physician       Date:  2016-10       Impact factor: 3.275

2.  Fusobacterium infections in children.

Authors:  Karen Arane; Ran D Goldman
Journal:  Can Fam Physician       Date:  2016-10       Impact factor: 3.275

3.  Fusobacterium nucleatum infections: clinical spectrum and bacteriological features of 78 cases.

Authors:  E Denes; O Barraud
Journal:  Infection       Date:  2016-01-18       Impact factor: 3.553

4.  Prospective Study of the Detection of Bacterial Pathogens in Pediatric Clinical Specimens Using the Melting Temperature Mapping Method.

Authors:  Yoji Uejima; Eisuke Suganuma; Takuma Ohnishi; Haruka Takei; Mihoko Furuichi; Satoshi Sato; Yutaka Kawano; Isao Kitajima; Hideki Niimi
Journal:  Microbiol Spectr       Date:  2022-06-08

Review 5.  Fusobacterium necrophorum otitis and mastoiditis in infants and young toddlers.

Authors:  T Stergiopoulou; T J Walsh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-03-07       Impact factor: 3.267

6.  Oral Pathogen Fusobacterium nucleatum Coaggregates With Pseudomonas aeruginosa to Modulate the Inflammatory Cytotoxicity of Pulmonary Epithelial Cells.

Authors:  Qian Li; Hongyan Wang; Lisi Tan; Shuwei Zhang; Li Lin; Xiaolin Tang; Yaping Pan
Journal:  Front Cell Infect Microbiol       Date:  2021-03-19       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.